Royalty Pharma plc (NASDAQ: RPRX – Get a rating) Director Mario Germano Giuliani sold 500 shares of the company in a transaction that took place on Thursday, August 25. The stock was sold at an average price of $44.00, for a total transaction of $22,000.00. Following completion of the transaction, the administrator now directly owns 9,076,640 shares of the company, valued at approximately $399,372,160. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this link.
Performance of Royalty Pharma shares
The NASDAQ RPRX fell $0.73 on Monday, hitting $42.32. 1,496,507 shares of the company were traded, against an average volume of 1,961,879. The company has a debt ratio of 0.68, a current ratio of 19.22 and a quick ratio of 19.22. The company’s 50-day moving average price is $42.98 and its two-hundred-day moving average price is $41.12. Royalty Pharma plc has a fifty-two week low of $34.86 and a fifty-two week high of $44.75. The company has a market capitalization of $25.70 billion, a price/earnings ratio of 55.91, a P/E/G ratio of 1.16 and a beta of 0.28.
Royalty Pharma dividend announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 15. Shareholders of record on Friday August 19 will receive a dividend of $0.19 per share. This represents a dividend of $0.76 on an annualized basis and a dividend yield of 1.80%. The ex-dividend date is Thursday, August 18. Royalty Pharma’s dividend payout ratio is currently 98.70%.
Institutional entries and exits
A d Tradewins
The safest option in the trades!
If you’re new to trading, you’ve probably heard the wrong word about options, that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering strategy, you will soon learn that the safest option for new accounts is the options themselves!
Major investors have recently changed their positions in the company. Signaturefd LLC increased its position in Royalty Pharma shares by 53.9% in the 1st quarter. Signaturefd LLC now owns 688 shares of the biopharmaceutical company worth $27,000 after purchasing an additional 241 shares during the period. Aurora Investment Counsel increased its stake in shares of Royalty Pharma by 0.9% during the first quarter. Aurora Investment Counsel now owns 29,939 shares of the biopharmaceutical company valued at $1,166,000 after acquiring 257 additional shares last quarter. Humankind Investments LLC increased its position in Royalty Pharma shares by 4.6% during the fourth quarter. Humankind Investments LLC now owns 6,122 shares of the biopharmaceutical company worth $244,000 after buying 269 additional shares in the last quarter. Gulf International Bank UK Ltd increased its position in shares of Royalty Pharma by 0.5% during the first quarter. Gulf International Bank UK Ltd now owns 57,580 shares of the biopharmaceutical company worth $2,243,000 after buying 300 more shares in the last quarter. Finally, Advisor Group Holdings Inc. increased its position in Royalty Pharma shares by 9.4% during the first quarter. Advisor Group Holdings Inc. now owns 4,265 shares of the biopharmaceutical company worth $151,000 after buying 366 additional shares in the last quarter. Hedge funds and other institutional investors hold 51.68% of the company’s shares.
Changes to analyst ratings
Several research companies have published reports on RPRX. Tigress Financial raised its price target on Royalty Pharma shares from $52.00 to $57.00 and gave the stock a “buy” rating in a Thursday, July 14, report. Citigroup raised its price target on Royalty Pharma shares from $50.00 to $60.00 in a Thursday, July 28 research report. UBS Group began covering Royalty Pharma shares in a research report on Monday, June 13. They set a “buy” rating and a price target of $47.00 for the company. Morgan Stanley raised its price target on Royalty Pharma shares from $48.00 to $51.00 and gave the stock an “overweight” rating in a Monday, August 8 research report. Finally, Scotiabank launched a hedge on Royalty Pharma shares in a report on Friday, May 13. They issued an “outperform” rating and a price target of $53.00 for the company. One equity research analyst gave the stock a hold rating and seven gave the stock a buy rating. According to data from MarketBeat.com, Royalty Pharma currently has an average rating of “Moderate Buy” and an average price target of $53.43.
Royal Pharma Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. She is also involved in the identification, evaluation and acquisition of royalties on various biopharmaceutical therapies. Additionally, the company collaborates with innovators from academic institutions, research hospitals and non-profit organizations, small and medium-sized biotech companies and pharmaceutical companies.
Read more
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Royalty Pharma was not on the list.
Although Royalty Pharma currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here
Comments are closed.